<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675749</url>
  </required_header>
  <id_info>
    <org_study_id>X-ALD_QoL</org_study_id>
    <nct_id>NCT04675749</nct_id>
  </id_info>
  <brief_title>Quality of Life in Women With X-linked Adrenoleukodystrophy</brief_title>
  <acronym>X-ALD_QoL</acronym>
  <official_title>Quality of Life in Female Carriers of X-linked Adrenoleukodystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leipzig University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leipzig University Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      X-linked adrenoleukodystrophy (X-ALD) is a hereditary white matter disorder caused by&#xD;
      mutations in the ABCD1 gene leading to disturbances in the metabolism of fatty acids. This&#xD;
      results in an accumulation of very long chain fatty acids (VLCFA) in the cells of the body&#xD;
      causing damage to the central nervous system (white matter of the brain and spinal cord). The&#xD;
      most common adult-onset X-ALD phenotype is adrenomyeloneuropathy (AMN), a slowly progressive&#xD;
      myelopathic variant with demyelination of the long tracts in the spinal cord, clinically&#xD;
      manifested as slowly progressive spastic paraparesis, sensory ataxia, bladder and sexual&#xD;
      dysfunction.&#xD;
&#xD;
      Although this rare disease is inherited X-linked, previous research revealed that up to 80%&#xD;
      of heterozygous women develop AMN symptoms during their lifetime.&#xD;
&#xD;
      The primary objectives of this study are 1) to assess the prevalence of symptomatic courses&#xD;
      in female carriers of X-ALD and 2) to determine the impact of AMN symptoms on the quality of&#xD;
      life of affected women in various areas (including everyday life, work, social network, sleep&#xD;
      quality, sexuality, mood).&#xD;
&#xD;
      Participants are asked to fill in self-report questionnaires, which are available in English,&#xD;
      German, and French and are provided electronically on the online platform Leuconnect&#xD;
      (https://www.leuconnect.com) launched by European Leukodystrophies Association (ELA)&#xD;
      international (https://elainternational.eu/).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with AMN Symptoms as Assessed by Adult ALD Clinical Score (AACS) - self-report version</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life in Symptomatic versus Asymptomatic Participants as Assessed by Self-report Questionnaire (SF-36)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>X-linked Adrenoleukodystrophy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Female carriers of X-ALD with or without AMN symptoms aged ≥18 years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained from the participant&#xD;
&#xD;
          -  Females ≥18 years at the time of consent, with proven X-ALD as defined by&#xD;
&#xD;
               1. Elevated VLCFA values, or&#xD;
&#xD;
               2. Mutation in ABCD1 gene&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No informed consent and assent&#xD;
&#xD;
          -  Current pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Köhler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leipzig University Medical Center, Leukodystrophy Outpatient Clinic, Department of Neurology, Leipzig, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Schäfer</last_name>
    <phone>+49-341-9720086</phone>
    <email>lisa.schaefer@medizin.uni-leipzig.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Leipzig University Medical Center, Leukodystrophy Outpatient Clinic, Department of Neurology, Leipzig, Germany</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Schäfer</last_name>
      <phone>+49-341-9720086</phone>
      <email>lisa.schaefer@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Köhler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Schäfer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adrenoleukodystrophy</keyword>
  <keyword>Adrenomyeloneuropathy</keyword>
  <keyword>Brain Diseases, Metabolic, Inborn</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Demyelinating Diseases</keyword>
  <keyword>White Matter Disorder</keyword>
  <keyword>Genetic Diseases, X-Linked</keyword>
  <keyword>Peroxisomal Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Female Carrier</keyword>
  <keyword>Adrenoleukodystrophy, women</keyword>
  <keyword>Heterozygous Carrier</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenoleukodystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

